Case number IPR2017-01093
Celltrion Inc. et al. v. Biogen, Inc. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Nov 14, 2017 | 14 | Notice of Refund Download | |
| Nov 9, 2017 | 13 | Petitioner's Request for Refund of Post-Institution Fee Download | |
| Oct 6, 2017 | 12 | Decision Denying Institution of Inter Partes Review Download | |
| Jul 10, 2017 | 2029 | Ex. 2029 Lu Declaration Download | |
| Jul 10, 2017 | 2023 | Ex. 2023 Carlson 1997 Download | |
| Jul 10, 2017 | 2015 | Ex. 2015 Arranz 1998 Download | |
| Jul 10, 2017 | 2011 | Ex. 2011 IPR2015-00418 Archived ECOG Website (12-12-1998) Download | |
| Jul 10, 2017 | 2016 | Ex. 2016 Dana 1998 Download | |
| Jul 10, 2017 | 2024 | Ex. 2024 Leget 1998 Download | |
| Jul 10, 2017 | 10 | Patent Owner Preliminary Response Download | |
| Jul 10, 2017 | 2021 | Ex. 2021 Multani-Grossbard 1998 Download | |
| Jul 10, 2017 | 2020 | Ex. 2020 Davis AACR 1998 Download | |
| Jul 10, 2017 | 2014 | Ex. 2014 McGrath 1997 - Excerpts Download | |
| Jul 10, 2017 | 2010 | Ex. 2010 Cabanillas 1992 Download | |
| Jul 10, 2017 | 2001 | Ex. 2001 Prior IPR Board Decision Download | |
| Jul 10, 2017 | 2025 | Ex. 2025 Czuczman 1996 Download | |
| Jul 10, 2017 | 2002 | Ex. 2002 Al-Ismail 1987 Download | |
| Jul 10, 2017 | 2009 | Ex. 2009 Schein et al. 1975 Cancer Download | |
| Jul 10, 2017 | 2008 | Ex. 2008 WayBack Machine Download | |
| Jul 10, 2017 | 2012 | Ex. 2012 Ezdinli 1987 Download | |
| Jul 10, 2017 | 2019 | Ex. 2019 Rohatiner 2005 Download | |
| Jul 10, 2017 | 2027 | Ex. 2027 Aviles 1997 Download | |
| Jul 10, 2017 | 11 | Patent Owner's Exhibit List Download | |
| Jul 10, 2017 | 2022 | Ex. 2022 Habermann Download | |
| Jul 10, 2017 | 2017 | Ex. 2017 Peterson 1997 Download | |
| Jul 10, 2017 | 2007 | Ex. 2007 Rosenberg 1991 Download | |
| Jul 10, 2017 | 2005 | Ex. 2005 2009-10-15 Restriction Requirement Download | |
| Jul 10, 2017 | 2028 | Ex. 2028 2010-05-10 IDS Download | |
| Jul 10, 2017 | 2018 | Ex. 2018 Chisesi 1991 Download | |
| Jul 10, 2017 | 2004 | Ex. 2004 Wiernik 1996 Download | |
| Jul 10, 2017 | 2026 | Ex. 2026 Grossbard 2002-Excerpts Download | |
| Jul 10, 2017 | 2013 | Ex. 2013 van Oers 2006 Download | |
| Jul 10, 2017 | 2006 | Ex. 2006 2010-01-29 Response to Restriction Requirement Download | |
| Jul 10, 2017 | 2003 | Ex. 2003 Hiddemann 1995 Download | |
| Apr 14, 2017 | 9 | NOTICE OF ACCEPTING CORRECTED PETITION Download | |
| Apr 12, 2017 | 1004 | (Corrected) Rituxan (Rituximab) label (Nov. 1997) Download | |
| Apr 12, 2017 | 8 | Notice of Corrected Exhibits Download | |
| Apr 12, 2017 | 1004 | (Corrected) Rituxan (Rituximab) label (Nov. 1997) Download | |
| Apr 12, 2017 | 1029 | (Corrected) Hochster H., et. al., Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, J. Clin. Oncol., 27(10) Download | |
| Apr 10, 2017 | 7 | Notice of Accord Filing Date Download | |
| Apr 5, 2017 | 5 | Power of Attorney Download | |
| Apr 5, 2017 | 5 | Power of Attorney Download | |
| Apr 5, 2017 | 6 | Mandatory Notice Download | |
| Apr 5, 2017 | 6 | Mandatory Notice Download | |
| Mar 17, 2017 | 1008 | ECOG 1496 Patient Consent Form (Corrected) Download | |
| Mar 17, 2017 | 1003 | Lossos Declaration (Corrected) Download | |
| Mar 17, 2017 | 1002 | Longo Declaration (Corrected) Download | |
| Mar 17, 2017 | 1008 | ECOG 1496 Patient Consent Form (Corrected) Download | |
| Mar 17, 2017 | 4 | Petitioner's Updated Mandatory Notice re Lead Backup Counsel Download | |
| Mar 17, 2017 | 3 | Certificate of Service re Corrected Exhibits Download | |
| Mar 17, 2017 | 1003 | Lossos Declaration (Corrected) Download | |
| Mar 17, 2017 | 1002 | Longo Declaration (Corrected) Download | |
| Mar 15, 2017 | 1058 | Public Hearing Transcript, Biological Response Modifiers Advisory Committee, Center for Biological Evaluation and Research, Food and Drug Administration, nineteenth meeting (July 25, 1997) ("FDA Transcript") Download | |
| Mar 15, 2017 | 1050 | Marcus, R. et al., CVP Chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105(4):1417-1423 (Feb. 15, 2005) ("Marcus 2005") Download | |
| Mar 15, 2017 | 1032 | Maloney, D.G. et al., IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma, J. Clin. Oncol., 15(10):3266-3274 (Oct. 1997) Download | |
| Mar 15, 2017 | 1046 | Rosenberg, S.A., The Low-Grade Non-Hodgkin's Lymphomas: Challenges and Opportunities, J. Clin. Oncol., 3(3):299-310 (Mar. 1985) Download | |
| Mar 15, 2017 | 1055 | Czuczman, M. et al., IDEC-C2B8/CHOP Chemoimmunotherapy in Patients with Low-Grade Lymphoma: Clinical and bcl-2 (PCR) Final Results, Blood, 88(10, Supp. 1):453a (Abstract 1799) (Nov. 15, 1996) Download | |
| Mar 15, 2017 | 1045 | Canellos, G.P. et al., Chemotherapy of the Non-Hodgkin's Lymphomas, Cancer, 42(2):932-940 (Aug. 1978 Download | |
| Mar 15, 2017 | 1005 | McNeil, C., Non-Hodgkin's Lymphona Trials in Elderly Look Beyond CHOP, J. Nat'l Cancer Inst. 90(4):266-67 (Feb. 18, 1998) ("McNeil 1998") Download | |
| Mar 15, 2017 | 1040 | Haq, M.M. et al., Doxorubicin-Induced Congestive Heart Failure in Adults, Cancer, 56(6):1361-1365 (Sept. 15, 1985) Download | |
| Mar 15, 2017 | 1001 | U.S. Patent No. 8,329,172 Download | |
| Mar 15, 2017 | 1071 | Demiden, A. et al., Chimeric Anti-CD20 Antibody (IDEC-C2B8) Is Apoptotic and Sensitizes Drug Resistant Human B Cell Lymphomas and Aids Related Lymphomas to the Cytotoxic Effect of CDDP, VP-16 and Toxins, Experimental Biology 95™ Download | |
| Mar 15, 2017 | 1016 | Reff, M.E. et al., Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20, Blood, 83(2):435-445 (Jan. 15, 1994) ("Reff 1994") Download | |
| Mar 15, 2017 | 1048 | Czuczman, M. et al., Phase II Clinical Trial of IDEC-C2B8/CHOP Combination Chemotherapy in Low Grade Lymphoma: Preliminary Results, Program/Proceedings Am. Soc. Clin. Oncol., 14:401 (Abstract 1261) (Mar. 1995) Download | |
| Mar 15, 2017 | 1056 | Czuczman, M. et al., IDEC-C2B8 clears bcl2 (t14;18) in patients (pts) with relapsed low grade or follicular lymphoma (LG/F NHL), P. Am. Assoc. Canc. Res., 38:84 (Abstract 565) (Mar. 1997) Download | |
| Mar 15, 2017 | 1034 | Hainsworth, J.D. et al., Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma, J. Clin. Oncol., 20(20):4261-4267 (Oct. 15, 2002) Download | |
| Mar 15, 2017 | 1024 | Coiffier B., et al., Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study, Blood, 92(6):1927-1932 (Sept. 15, 1998) Download | |
| Mar 15, 2017 | 1020 | Czuczman, M.S. et al., Treatment of patients with Low-grade B-Cell Lymphoma with the Combination of Chimeric Anti-20 Monoclonal Antibody and CHOP Chemotherapy, J. Clin. Oncol. 17(1):268-276 (Jan. 1999) ("Czuczman 1999") Download | |
| Mar 15, 2017 | 1054 | Maloney, D.G. et al., Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma, Blood, 84(8):2457-2466 (Oct. 15, 1994) ("Maloney 1994") Download | |
| Mar 15, 2017 | 1052 | Piro, L. et al., RITUXAN™ (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma, Blood 90(10, Supp. 1):510a (Abstract 2272) (Nov. 15, 1997) Download | |
| Mar 15, 2017 | 1066 | E1496 Forms Packet Download | |
| Mar 15, 2017 | 1051 | Smith, M.R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance, Oncogene, 22(47):7359-7368 (Oct. 20, 2003) Download | |
| Mar 15, 2017 | 1026 | Palmieri, G. et al., Maintenance therapy with recombinant interferon alpha-2B (aIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL), Oncol. Rep., 3(4):733-735 (July/Aug. 1996) Download | |
| Mar 15, 2017 | 1021 | Leget, G.A. et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol. 10(6):548-551 (Nov. 1998) Download | |
| Mar 15, 2017 | 1063 | Czuczman, M. et al., RituxanTM/CHOP Chemo Immunotherapy in Patients with Low-Grade or Follicular (LG/F) Non-Hodgkin's Lymphoma (NHL), J. Immunother., 20(5):401 (1997) Download | |
| Mar 15, 2017 | 1038 | U.S. Provisional Application No. 60/096,180 ("the '180 provisional application") Download | |
| Mar 15, 2017 | 1039 | Sriskandan, S. et al., Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin, Postgrad. Med. J., 70(828):759-761 (Oct. 1994) Download | |
| Mar 15, 2017 | 2 | Petition for Inter Partes Review of U.S. Patent No. 8,329,172 Download | |
| Mar 15, 2017 | 1014 | Stashenko, P. et al., Characterization of a Human B Lymphocyte-Specific Antigen, J. Immunol., 125(4):1678-1685 (Oct. 1980) ("Stashenko 1980") Download | |
| Mar 15, 2017 | 1042 | McLaughlin, P. et al., Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, J. Clin. Oncol., 16(8):2825-2833 (Aug. 1998) ("McLauglin 1998") Download | |
| Mar 15, 2017 | 1013 | Nadler, L.M. et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen, Cancer Res., 40(9):3147-3154 (Sept. 1980) ("Nadler 1980") Download | |
| Mar 15, 2017 | 1036 | U.S. Application No. 09/372,202 ("the '202 application") Download | |
| Mar 15, 2017 | 1 | Peitioner's Power of Attorney Download | |
| Mar 15, 2017 | 1015 | Anderson, K.C. et al., Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A model of Human B Cell Differentiation, Blood, 63(6):1424-1433 (June 1984) ("Anderson 1984") Download | |
| Mar 15, 2017 | 1025 | Horning S., Treatment Approaches to the Low-Grade Lymphomas, Blood 83(4):881-884 (Feb. 15, 1994) Download | |
| Mar 15, 2017 | 1006 | Bishop, J.F. et al., A Randomized Trial of High Dose Cyclophosphamide, Vincristine, and Prednisone Plus or Minus Doxorubicin (CVP versus CAVP) with Long-Term Follow-Up in Advanced Non-Hodgkin's Lymphoma, Leukemia, 1(6):508-513 (June 1987) Download | |
| Mar 15, 2017 | 1031 | Steward, W.P. et al., Maintenance Chlorambucil After CVP in the Management of Advanced Stage, Low-Grade Histologic Type Non-Hodgkin's Lymphoma: A Randomized Prospective Study With an Assessment of Prognostic Factors, Cancer 61(3):441-447 (Feb. 1, 1988) Download | |
| Mar 15, 2017 | 1062 | Czuczman, M.S. et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, Blood 86(10, Supp. 1):55a (Abstract 206) (Nov. 15, 1995) Download | |
| Mar 15, 2017 | 1009 | ECOG E 1496 Protocol (1998) Download | |
| Mar 15, 2017 | 1061 | U.S. Application No. 13/524,896, Feb. 5, 2014 Amendment and Response to Office Action Download | |
| Mar 15, 2017 | 1023 | Grillo-Lopez, A.J. et al., Overview of the Clinical Development of Rituximab: First Monoclonal Antibody Approved for the Treatment of Lymphoma, Semin. Oncol. 26(5, Supp. 14):66-73 (Oct. 1999) Download | |
| Mar 15, 2017 | 1022 | Maloney, D.G. and Press, O.W., Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies, Oncology 12(10, Supp. 8):63-76 (Oct. 1998) Download | |
| Mar 15, 2017 | 1007 | Dana, B. et al., Long-Term Follow-Up of Patients With Low-Grade Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy,J.Clin. Oncol., 11(4):644-651 (Apri. 1993) Download | |
| Mar 15, 2017 | 1049 | ECOG Protocols Active as of 05/19/98 Download | |
| Mar 15, 2017 | 1047 | Kimby, E. et al., Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden, Ann. Oncol., 5(Supp. 2):67-71 (1994) Download | |
| Mar 15, 2017 | 1068 | E1496 On Study Dates Download | |
| Mar 15, 2017 | 1027 | Maloney, D.G. et al., IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma, Blood, 90(6): 2188-2195 (Sept. 15, 1997) Download | |
| Mar 15, 2017 | 1018 | DeVita, V. T., Jr. et al., Chapter 44: Hodgkin's Disease and the Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice of Oncology, Second Edition (DeVita, Jr. et al., eds., 1985) Download | |
| Mar 15, 2017 | 1033 | Berinstein, N.L., et al., Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann. Oncol., 9:995-1001 (July 1998) Download | |
| Mar 15, 2017 | 1064 | Demidem A. et al., Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs, Cancer Biother. Radio., 12(3):177-186 (1997) Download | |
| Mar 15, 2017 | 1053 | Czuczman, M.S. et al., IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: interim clinical and bcl-2 (PCR) results, Ann. Oncol., 7(Supp. 1):56 (Abstract 191) (1996) Download | |
| Mar 15, 2017 | 1057 | Harris, N.L. et al., A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group, Blood, 84(5):1361-1392 (Sept. 1, 1994) Download | |
| Mar 15, 2017 | 1028 | Czuczman M.S., et al., Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up, J. Clin. Oncol., 22(23):4711-4716 (Dec. 1, 2004) Download | |
| Mar 15, 2017 | 1012 | IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997, filed with the U.S. Securities and Exchange Commission Download | |
| Mar 15, 2017 | 1019 | U.S. Application No. 11/840,956 ("the '956 application") Download | |
| Mar 15, 2017 | 1017 | Foon, K.A. & Fisher, R.I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, 1076-1096 (Beutler, E. et al., eds., 1995) Download | |
| Mar 15, 2017 | 1011 | Hainsworth, J.D. et al., Rituximab Induction and Maintenance Therapy in Patients (pts) with Previously Untreated Low-Grade Non-Hodgkin's Lymphoma (NHL); Prelimiary Results of a Minnie Pearl Cancer Research Network Phase II Trial Download | |
| Mar 15, 2017 | 1044 | Hoppe, T.E. et al., The Treatment of Advanced Stage Favorable Histology Non-Hodgkin's Lymphoma: A Preliminary Report of a Randomized Trial Comparing Single Agent Chemotherapy, Combination Chemotherapy, and Whole Body Irradiation Download | |
| Mar 15, 2017 | 1035 | White, C., Rituximab Immunotherapy for Non-Hodgkin's Lymphoma, Cancer Biother. Radio., 14(4):241-50 (Aug. 1999) ("White 1999") Download | |
| Mar 15, 2017 | 1060 | Ruuls, S.R. et al., Novel human antibody therapeutics: the age of the Umabs, Biotechnol. J., 3:1157-1171 (2008) Download | |
| Mar 15, 2017 | 1010 | Grossbard, M.L. and Multani, P.S., The McLaughlin, et. al. Article [Clinical STatus and Optimal Use of Rituximab for B-Cell Lymphomas] Reviewed, Ongology, 12(12):1769-1781 (Dec. 1, 1998) Download | |
| Mar 15, 2017 | 1029 | Hochster H., et al., Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, Download | |
| Mar 15, 2017 | 1029 | Hochster H., et al., Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, Download | |
| Mar 15, 2017 | 1002 | Expert Declaration of Dr. Walter Longo Download | |
| Mar 15, 2017 | 1003 | Expert Declaration of Dr. Izidore Lossos Download | |
| Mar 15, 2017 | 1004 | Rituxan 1997 Label Download | |
| Mar 15, 2017 | 1008 | Eastern Cooperative Oncology Group 9"ECOG") E1496 Patient Consent Form Download |
